Skip to content

Clinical Effect of Nalbuphine and Oxycodone combined with Propofol for Patients with Hysteroscopy

Clinical Effect of Nalbuphine and Oxycodone combined with Propofol for Patients with Hysteroscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030192
Enrollment
Unknown
Registered
2020-02-25
Start date
2017-01-02
Completion date
Unknown
Last updated
2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless Hysteroscopy

Interventions

Group P:propofol 1.5mg/kg
Group PN:nalbuphine 0.1mg/kg and propofol 1.5mg/kg
Group PQ:oxycodone 0.05mg/kg and propofol 1.5mg/kg

Sponsors

the Fourth Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) ASA grade was I-II; 2) 18 to 65 years of age; 3) weight of 50-80 kg.

Exclusion criteria

Exclusion criteria: 1) emergency patients; 2) severe abnormalities in heart, lung, kidney, liver, and other functions; 3) sleep apnea syndrome or difficult airways; 4) bronchial asthma; 5) recent respiratory infections; 6) obvious abnormalities in preoperative ECG, blood routine, electrolytes, and other tests; 7) history of allergies to narcotic drugs; 8) history of sedation, analgesics, or alcohol abuse; 9) mental illness.

Design outcomes

Primary

MeasureTime frame
Blood Pressure;Heart Rate;SpO2;the total amount of propofol;recovery time;VAS score in 10 minutes after the operation;the proportion of VAS score more than 4;

Secondary

MeasureTime frame
operation time;the surgeon's satisfaction;

Countries

China

Contacts

Public ContactJia Li

the Fourth Hospital of Hebei Medical University

281575038@qq.com+86 13933089766

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026